The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Malone, David F G ^a   Falconer, Karolin ^b   Weiland, Ola ^b   Sandberg, Johan K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; CD14 ANTIGEN; CD18 ANTIGEN; INTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; INTERLEUKIN 18; OLIGOPEPTIDE; SERINE PROTEINASE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; AGED; BLOOD; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; IMMUNITY, INNATE; INTERFERONS; INTERLEUKIN-18; MALE; MIDDLE AGED; OLIGOPEPTIDES; RETROSPECTIVE STUDIES; RIBAVIRIN; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84926522073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105665     Document Type: Article

References (33)

1. Degasperi E, Viganò M, Aghemo A, Lampertico P, Colombo M (2013) PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history. Expert Rev Anti Infect Ther 11: 459-474.
2. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46: 1548-1563. (Pubitemid 350155537)
3. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039. (Pubitemid 351754525)
4. Gonzalez VD, Landay AL, Sandberg JK (2010) Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 135: 12-25.
5. Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32: 513-545.
6. Hofmann WP, Zeuzem S (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8: 257-264.
7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
8. Poordad F, McCone jr J, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
9. Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM (2013) Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 10: 713-728.
10. Heim MH (2013) 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 13: 535-542.
11. Parekh P, Shiffman M (2014) The role of interferon in the new era of hepatitis C treatments. Expert Rev Gastroenterol Hepatol 8: 649-656.
12. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, et al. (1996) Human monocyte CD14 is upregulated by lipopolysaccharide. Infect Immun 64: 1762-1769. (Pubitemid 26129837)
13. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, et al. (2011) Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterol 141: 1220.
14. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371. (Pubitemid 44924494)
15. Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, et al. (2013) Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic steatohepatitis. PloS One 8: e65211.
16. Litzman J, Nechvatalova J, Xu J, Ticha O, Vlkova M, et al. (2012) Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia. Clin Exp Immunol 170: 321-332.
17. Paquin Proulx D, Santos BAN, Carvalho KI, Toledo-Barros M, de Oliveira AKB, et al. (2013) IVIg Immune Reconstitution Treatment Alleviates the State of Persistent Immune Activation and Suppressed CD4 T Cell Counts in CVID. PloS One 8: e75199.
18. Pan Z, Zhou L, Hetherington CJ, Zhang DE (2000) Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J Biol Chem 275: 36430-36435.
19. Meuleman P, Steyaert S, Libbrecht L, Couvent S, Van Houtte F, et al. (2006) Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. Clin Chim Acta 366: 156-162. (Pubitemid 43330976)
20. Leeansyah E, Malone DF, Anthony DD, Sandberg JK (2013) Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 8: 117-124.
21. Anthony DD, Conry SJ, Medvik K, Sandhya Rani MR, Falck-Ytter Y, et al. (2012) Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis 206: 969-973.
22. Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, et al. (2012) Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PloS One 7: e32028.
23. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, et al. (1998) Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leuk Biol 63: 658-664. (Pubitemid 28274825)
24. Van de Veerdonk FL, Wever PC, Hermans MHA, Fijnheer R, Joosten LAB, et al. (2012) IL-18 serum concentration is markedly elevated in acute EBV infection and can serve as a marker for disease severity. J Infect Dis 206: 197-201.
25. Finotto S, Siebler J, Hausding M, Schipp M, Wirtz S, et al. (2004) Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut 53: 392-400. (Pubitemid 38241337)
26. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, et al. (2006) Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 36: 144-150.
27. Bouzgarrou N, Hassen E, Schvoerer E, Stoll-Keller F, Bahri O, et al. (2008) Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 80: 607-614. (Pubitemid 351358557)
28. Sharma A, Chakraborti A, Das A, Dhiman RK, Chawla Y (2009) Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 128: 22.
29. Vecchiet J, Falasca K, Cacciatore P, Zingariello P, Dalessandro M, et al. (2005) Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci 35: 415-422. (Pubitemid 41579572)
30. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, et al. (2008) Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57: 516-524.
31. Pearlman BL, Ehleben C (2014) Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology 59: 71-77.
32. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz EM, et al. (2014) Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response. J Hepatol 60: 748-756.
33. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370: 211-221.